Plexxikon’s patents are for compounds it began developing in 2005 that help reduce cancer cell growth. Plexxikon relied on its inventions to co-develop the skin cancer drug Zelboraf with Roche. Novartis failed to persuade the jury that the patents are invalid.
The verdict on Thursday is a blow to Novartis, whose Tafinlar and a companion melanoma drug Mekinist generated $1.5 billion in revenue last year, and $393 million in the first quarter.
Novartis “is considering further its ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.